首页 › 胶质母细胞瘤 › 田纳西州 › Nashville
Nashville TN 胶质母细胞瘤临床试验
9项针对 胶质母细胞瘤的研究正在 Nashville及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
招募中1/2 期
- Vanderbilt University Medical Center, Nashville
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
招募中1/2 期
- SCRI Oncology Partners, Nashville
Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma
招募中1 期
- Vanderbilt University/Ingram Cancer Center, Nashville
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
招募中3 期
- Vanderbilt-Ingram Cancer Center, Nashville
DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM)
招募中2 期
- Vanderbilt-Ingram Cancer Center, Nashville
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
招募中早期 I 期
- Vanderbilt University Medical Center, Nashville
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
招募中1 期
- Sarah Cannon, SCRI Oncology Partners, Nashville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Nashville
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
招募中1/2 期
- Tennessee Oncology, Nashville
其他城市的 胶质母细胞瘤试验
- New York City, NY30 项研究
- Boston, MA28 项研究
- Houston, TX26 项研究
- Los Angeles, CA24 项研究
- Durham, NC20 项研究
- San Francisco, CA17 项研究
- Chicago, IL15 项研究
- Washington, DC15 项研究
- Columbus, OH14 项研究
- Miami, FL14 项研究
- Rochester, MN13 项研究
- Jacksonville, FL13 项研究
Nashville的其他研究
- 非小细胞肺癌97 项研究
- 乳腺癌81 项研究
- 转移性癌症70 项研究
- 结直肠癌69 项研究
- 癌症（所有类型）65 项研究
- 卵巢癌49 项研究
- 前列腺癌43 项研究
- 肺癌40 项研究
- 头颈鳞状细胞癌39 项研究
- 胰腺癌39 项研究
- 子宫内膜癌38 项研究
- 黑色素瘤33 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。